Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EPS (Basic) (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed EPS (Basic) for 6 consecutive years, with -$0.36 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) fell 71.43% year-over-year to -$0.36, compared with a TTM value of -$1.88 through Sep 2025, down 27.03%, and an annual FY2024 reading of -$1.55, up 18.85% over the prior year.
  • EPS (Basic) was -$0.36 for Q3 2025 at Barinthus Biotherapeutics, up from -$0.52 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.42 in Q2 2022 and bottomed at -$1.9 in Q1 2021.
  • Average EPS (Basic) over 5 years is -$0.37, with a median of -$0.4 recorded in 2024.
  • The sharpest move saw EPS (Basic) surged 4100.0% in 2022, then plummeted 785.71% in 2023.
  • Year by year, EPS (Basic) stood at -$0.38 in 2021, then crashed by 50.0% to -$0.57 in 2022, then grew by 22.81% to -$0.44 in 2023, then dropped by 15.91% to -$0.51 in 2024, then increased by 29.41% to -$0.36 in 2025.
  • Business Quant data shows EPS (Basic) for BRNS at -$0.36 in Q3 2025, -$0.52 in Q2 2025, and -$0.49 in Q1 2025.